Coverage
-
August 16, 2016
A UCB Inc. patent for the anti-convulsant Vimpat is valid, a Delaware federal judge said in an opinion unsealed on Monday, blocking attempts by Actavis Inc., Mylan Pharmaceuticals Inc., Apotex Inc.. and several other drugmakers to make and sell a generic versison of the drug.
1 other articles on this case.
View all »